Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Renal Cell Carcinoma: early-phase trial registry
1 of 5 indexed Recurrent Renal Cell Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 1 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Recurrent Renal Cell Carcinoma: 5 US clinical trials tracked, 1 recruiting.
Recurrent Renal Cell Carcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is University of Southern California, running 2 of these trials.
Enrollment posture brief
Registry condition recurrent-renal-cell-carcinoma
OPEN 1 | RECR 20% | LATE 0 | EARLY 4 | RANK #3391 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (20% recruiting · 10 trials)
Recurrent Renal Cell Carcinoma lists 1 open slots (20% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Renal Cell Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Renal Cell Carcinoma is recruiting below its size-band peers.
1 of 5 indexed trials (20%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Renal Cell Carcinoma research.
University of Southern California accounts for 2 of 5 trials (40%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Renal Cell Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 62 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.
-
Recurrent Renal Cell Carcinoma research is mostly interventional.
4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
Contrast-Enhanced Ultrasound Imaging for Diagnosing Recurrent Renal Cell Carcinoma (RCC) Post Ablation
john eisenbrey
NCT05641935
Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
University of Southern California
NCT03092856
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT02298959
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
University of Southern California
NCT02664883
Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
NCT00126594
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Renal Cell Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Renal Cell Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Renal Cell Carcinoma page
5 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Recurrent Renal Cell Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Southern California sponsors the most Recurrent Renal Cell Carcinoma trials on record, review their full trial history before evaluating a specific study. See University of Southern California's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Renal Cell Carcinoma condition card totals 5 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.